On Tuesday, Northstar Asset Management Group Inc. (NYSE:NSAM)’s shares surged 5.35% to $22.45, after the U.S. Labor Department projected some widespread changes.
The proposals would require brokers that offer retirement advice to sign “best interest” contracts with investors in an effort to make sure that customers are not steered into high-fee products, according to Reuters.
The news sent the global asset managemnet firm higher near the close of trading.
Northstar Asset Management Group Inc. provides asset administration and other services in the United States and internationally. It also offers securitization transaction services. The company is based in New York, New York. Northstar Asset Administration Group Inc. (NYSE:NSAM) operates independently of NorthStar Realty Finance Corp. as of June 30, 2014.
Northern Oil and Gas, Inc. (NYSEMKT:NOG)’s shares gained 5.20% to $9.11, during the last trading session on Tuesday, as NOG, declared that Michael Reger, Chairman and CEO, is planned to present at the IPAA Oil and Gas Investment Symposium (OGIS) New York Conference on Tuesday, April 21, 2015 at 2:00 p.m. ET.
Northern Oil and Gas, Inc., an independent energy company, engages in the attainment, exploration, development, and production of oil and natural gas properties in the United States. It primarily holds interest in the Bakken and Three Forks formations in the Williston Basin of North Dakota and Montana.
At the end of Tuesday’s trade, Galena Biopharma, Inc. (NASDAQ:GALE)’s shares gained 5.07% to $1.45, after GALE declared the completion of enrollment in the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax(TM) is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.
As anticipated, Galena over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat (ITT) population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment (SPA), called for 700 patients; and, the Company anticipates this higher number of ITT patients will raise the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is presently predictable to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a total of 141 events (recurrence or death) occur, whichever comes later.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
Finally, Callon Petroleum Company (NYSE:CPE), ended its Tuesday’s trading session with 5% gain, and closed at $8.61, as CPE declared that senior administration plans to take part in the forthcoming investor event:
OGIS New York
The Company will present at the 21st Annual Oil & Gas Investment Symposium, hosted by the Independent Petroleum Association of America New York, NY on Tuesday, April 21, 2015 at 9:35 am Eastern Daylight Time.
Callon Petroleum Company engages in the exploration, development, attainment, and production of oil and natural gas properties in the Permian Basin in West Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
